Curated News
By: NewsRamp Editorial Staff
September 12, 2025
GeoVax's Multi-Antigen COVID Vaccine Shows Strong Results in High-Risk Patients
TLDR
- GeoVax's GEO-CM04S1 vaccine outperforms standard mRNA vaccines in immunocompromised patients, offering a competitive edge in the multi-billion dollar underserved market.
- GEO-CM04S1 uses a Modified Vaccinia Ankara vector to express both Spike and Nucleocapsid proteins, stimulating robust T-cell and cross-variant antibody responses.
- This vaccine addresses urgent unmet needs for immunocompromised patients, making the world safer for vulnerable populations against COVID-19 variants.
- GeoVax's multi-antigen approach generates durable immunity against Omicron subvariants, with an updated KP.2 construct advancing to trials in 2026.
Impact - Why it Matters
This development is crucial because immunocompromised individuals, such as those with blood cancers or post-transplant status, remain highly vulnerable to COVID-19 despite existing vaccines, which often provide inadequate protection. A more effective vaccine for this population could reduce severe illness, hospitalizations, and deaths, easing healthcare burdens and improving quality of life for millions globally. Additionally, the multi-antigen approach may offer broader and longer-lasting immunity against evolving variants, potentially shaping future pandemic preparedness and vaccine strategies beyond COVID-19.
Summary
GeoVax Labs, Inc., a clinical-stage biotechnology company, has announced promising interim results for its next-generation multi-antigen COVID-19 vaccine candidate, GEO-CM04S1, presented at the 6th ESCMID Conference on Vaccines in Lisbon. The data, shared by Chief Medical Officer Kelly T. McKee, Jr., MD, MPH, revealed strong immune responses in high-risk immunocompromised patients, including those with blood cancers and chronic lymphocytic leukemia (CLL), with no serious adverse events reported. The vaccine demonstrated robust T-cell and cross-variant antibody responses that exceeded those of standard mRNA vaccines, meeting its primary endpoint in the CLL trial while the comparator did not.
GEO-CM04S1 is based on a Modified Vaccinia Ankara (MVA) vector and uniquely expresses both the Spike and Nucleocapsid proteins of SARS-CoV-2, designed to stimulate comprehensive immunity. It is currently in three Phase 2 trials: as a primary vaccine for immunocompromised patients, a booster for CLL patients, and a booster for healthy adults previously vaccinated with mRNA vaccines. An updated construct incorporating the Omicron KP.2 Spike gene is slated for a 2026 trial, positioning GeoVax at the forefront of next-generation vaccines. Chairman & CEO David Dodd emphasized the platform's competitive advantage in addressing unmet needs in a multi-billion-dollar global market, with potential broader applications across infectious diseases. For more details, visit www.geovax.com.
Source Statement
This curated news summary relied on content disributed by NewMediaWire. Read the original source here, GeoVax's Multi-Antigen COVID Vaccine Shows Strong Results in High-Risk Patients
